Point-of-Care Monitoring of Enoxaparin in the Presence of GpIIb/IIIa Combined Therapy During Percutaneous Coronary Interventions

Plastic Surgical Nursing

Volumn 4, Issue 1, 2005, Pages 30-35

  Rouby, Soumaya El ^a   Cohen, Marc ^b   Gonzales, Andrea ^b   Hoppensteadt, Debra ^c   Zucker, Marcia L ^a   Lee, Ted ^a   Khalid, Khaula ^b   Fareed, Jawed ^c   LaDuca, Frank M ^a  

^a ITC   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

enoxaparin; GpIIb IIIa; percutaneous coronary intervention; point of care testing

Indexed keywords

EID: 85026166509     PISSN: 07415206     EISSN: 15501841     Source Type: Journal    
DOI: 10.1097/01.poc.0000157177.83327.3f     Document Type: Article

References (32)

1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (ESSENCE). N Engl J Med. 1997;337:447-452.
2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction TIMI-11B trial. Circulation. 1999;100:1593-1601.
3. Goodman SG, Fitchett D, Armstrong PW, et al On behalf of the INTERACT Trial Investigators. The INTegrelin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment Trial. Circulation. 2003;107:238-244.
4. Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol. 2003;41:55S-61S.
5. Klein W, Buchwald A, Hillis WS, et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC Study). Fragmin in Unstable Coronary Artery Disease. Circulation. 1997;4:E30-E34.
6. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658-663.
7. Fox KAA, Antman EM, Cohen M, et al. For the ESSENCE/TIMI 11B Investigators. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol. 2002;90:47-82.
8. Aslam MS, Sundberg S, Sabri MN, et al. Pharmacokinetic of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Intervent. 2002;57:187-190.
9. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) Study. Am Heart J. 2003;146:628-634.
10. Lee DS, Bhatt DL, Moliterno DJ, et al. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol. 2004;16:46-51.
11. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
12. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:139-195.
13. Kereiakes DJ, Grines C, Fry E, et al for the National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invasive Cardiol. 2001;13:272-278.
14. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002;14:439-442.
15. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943-1950.
16. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003;289:331-342.
17. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J Am Coll Cardiol. 2003;41:20-25.
18. Carnendran L, Borkowski R, Markabawi B, et al. Safety and efficacy of low-dose intravenous enoxaparin and GPIIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol. 2003;15:235-238.
19. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study. Catheter Cardiovasc Interv. 2004;61:163-170.
20. Ferguson JJ, Antman EM, Bates ER, et al. NICE-3 investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) Study. Am Heart J. 2003;1464:628-634.
21. Khosla S, Kunjummen B, Guerrero M, et al. Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention. Am J Ther. 2002;6:488-491.
22. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol. 2003;41:394-403.
23. Lawrence M, Mixon TA, Cross D, et al. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Intervent. 2004;61:52-55.
24. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol. 2003;42:1132-1139.
25. Saw J, Kereiakes DJ, Mahaffey KW, et al. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res. 2003;112:301-306.
26. Hoppensteadt DA, Jeske W, Fareed J, et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis. 1995;suppl 1:S57-S64.
27. Ammar T, Scudder LE, Coller BS. in vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 1997;95:614-617.
28. Holmes MB, Schneider DJ, Hayes MG, et al. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation. 2000;102:2051-2057.
29. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
30. Dauerman HL, Ball SA, Goldberg RJ, et al. Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. J Thromb Thrombolysis. 2002;13:127-132.
31. Dangas G, Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Am Heart J. 1999;138:S16-S23.
32. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238-244.